Humedix Co., Ltd. (200670.KQ)
KRW 42800.0
(3.38%)
KRW 42800.0
(3.38%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 21.91 Billion KRW | -75.1% |
| 2022 | 88.02 Billion KRW | 15.76% |
| 2021 | 76.04 Billion KRW | 86.52% |
| 2020 | 40.76 Billion KRW | 139.12% |
| 2019 | 17.04 Billion KRW | 16.8% |
| 2018 | 14.59 Billion KRW | -7.79% |
| 2017 | 15.83 Billion KRW | -12.78% |
| 2016 | 18.15 Billion KRW | 215.39% |
| 2015 | 5.75 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 26.57 Billion KRW | 21.27% |
| 2024 Q2 | 21.04 Billion KRW | -20.8% |
| 2023 Q3 | 26.21 Billion KRW | -17.07% |
| 2023 FY | 21.91 Billion KRW | -75.1% |
| 2023 Q2 | 31.61 Billion KRW | -40.68% |
| 2023 Q4 | 21.91 Billion KRW | -16.41% |
| 2023 Q1 | 53.29 Billion KRW | -39.45% |
| 2022 FY | 88.02 Billion KRW | 15.76% |
| 2022 Q4 | 88.02 Billion KRW | 14.32% |
| 2022 Q3 | 77 Billion KRW | 2.67% |
| 2022 Q2 | 74.99 Billion KRW | -4.33% |
| 2022 Q1 | 78.39 Billion KRW | 3.08% |
| 2021 FY | 76.04 Billion KRW | 86.52% |
| 2021 Q3 | 65.29 Billion KRW | 1.33% |
| 2021 Q4 | 76.04 Billion KRW | 16.46% |
| 2021 Q2 | 64.44 Billion KRW | 142493.06% |
| 2021 Q1 | 45.19 Million KRW | 10.85% |
| 2020 Q3 | 41.37 Million KRW | 2.82% |
| 2020 FY | 40.76 Billion KRW | 139.12% |
| 2020 Q4 | 40.76 Million KRW | -1.47% |
| 2020 Q1 | 20.35 Million KRW | 19.4% |
| 2020 Q2 | 40.24 Million KRW | 97.69% |
| 2019 Q4 | 17.04 Million KRW | -6.53% |
| 2019 FY | 17.04 Billion KRW | 16.8% |
| 2019 Q3 | 18.24 Million KRW | 9.17% |
| 2019 Q2 | 16.7 Million KRW | -31.59% |
| 2019 Q1 | 24.42 Million KRW | 71.62% |
| 2018 Q3 | 14.7 Million KRW | -5.38% |
| 2018 FY | 14.59 Billion KRW | -7.79% |
| 2018 Q1 | 21.44 Million KRW | 35.5% |
| 2018 Q4 | 14.23 Million KRW | -3.19% |
| 2018 Q2 | 15.53 Million KRW | -27.57% |
| 2017 FY | 15.83 Billion KRW | -12.78% |
| 2017 Q4 | 15.83 Million KRW | -17.75% |
| 2017 Q1 | 25.07 Million KRW | 38.18% |
| 2017 Q2 | 22.64 Million KRW | -9.73% |
| 2017 Q3 | 19.24 Million KRW | -14.99% |
| 2016 Q4 | 18.15 Million KRW | 0.0% |
| 2016 FY | 18.15 Billion KRW | 215.39% |
| 2016 Q1 | - KRW | 0.0% |
| 2015 FY | 5.75 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 53.19 Billion KRW | 58.806% |
| CMG Pharmaceutical Co., Ltd. | 40.02 Billion KRW | 45.254% |
| Celltrion Pharm, Inc. | 264.97 Billion KRW | 91.73% |
| Huons Global Co., Ltd. | 407.28 Billion KRW | 94.619% |
| DongKook Pharmaceutical Co., Ltd. | 263.36 Billion KRW | 91.679% |
| Enzychem Lifesciences Corporation | 16.91 Billion KRW | -29.528% |
| Boditech Med Inc. | 30.48 Billion KRW | 28.114% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | 67.689% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -145.713% |
| Huons Co., Ltd. | 206.87 Billion KRW | 89.407% |
| BNC Korea Co., Ltd. | 21.94 Billion KRW | 0.143% |
| AptaBio Therapeutics Inc. | 38.19 Billion KRW | 42.62% |